IPA Valuation
Immunoprecise Antibodies Ltd
$
0.495
- Overview
- Forecast
- Valuation
IPA Relative Valuation
IPA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IPA is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for IPA's competitors is 3.69, providing a benchmark for relative valuation. Immunoprecise Antibodies Ltd Corp (IPA) exhibits a P/S ratio of 1.10, which is -70.11% above the industry average. Given its robust revenue growth of -1.13%, this premium appears unsustainable.
People Also Watch
AAPL
Apple Inc
211.260
USD
-0.09%
TSLA
Tesla Inc
349.980
USD
+2.09%
NVDA
NVIDIA Corp
135.400
USD
+0.42%
MSFT
Microsoft Corp
454.270
USD
+0.25%
META
Meta Platforms Inc
640.340
USD
-0.55%
ORCL
Oracle Corp
160.490
USD
+0.68%
AVGO
Broadcom Inc
228.610
USD
-1.73%
WMT
Walmart Inc
98.240
USD
+1.96%
AMZN
Amazon.com Inc
205.590
USD
+0.20%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
FAQ
Is Immunoprecise Antibodies Ltd (IPA) currently overvalued or undervalued?
Immunoprecise Antibodies Ltd (IPA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.10 is considered Undervalued compared with the five-year average of 5.21. The fair price of Immunoprecise Antibodies Ltd (IPA) is between 1.02 to 3.49 according to relative valuation methord. Compared to the current price of 0.49 USD , Immunoprecise Antibodies Ltd is Undervalued By 51.39% .
What is Immunoprecise Antibodies Ltd (IPA) fair value?
How does IPA's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunoprecise Antibodies Ltd (IPA) as of May 18 2025?
What is the current FCF Yield for Immunoprecise Antibodies Ltd (IPA) as of May 18 2025?
What is the current Forward P/E ratio for Immunoprecise Antibodies Ltd (IPA) as of May 18 2025?